Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • gevokizumab

    - PMLiVE

    Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies

    The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population

    - PMLiVE

    Novartis and Matchpoint enter inflammatory disease partnership worth $1bn

    The companies will focus on inflammatory diseases that have been historically difficult to treat

    - PMLiVE

    Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m

    The common skin condition affects approximately 40 million people worldwide

    EU flag

    EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases

    The drug has been approved for rheumatoid arthritis, giant cell arteritis and other indications

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    Sanofi/Regeneron’s Dupixent approved by EC for younger eosinophilic oesophagitis patients

    Dupixent is now the first drug in the EU indicated for use in this patient population

    - PMLiVE

    Merck and Mestag enter inflammatory disease partnership worth up to $1.9bn

    The agreement will see Mestag use its platform designed to model the pathogenic role of fibroblasts

    EU flag

    EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

    The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

    - PMLiVE

    AbbVie expands inflammatory disease pipeline with $250m Celsius acquisition

    The deal includes an anti-TREM1 antibody that has completed a phase 1 study in inflammatory bowel disease

    - PMLiVE

    Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition

    The company will gain rights to Alpine’s lead molecule, povetacicept, to treat IgA nephropathy

    - PMLiVE

    AbbVie to expand inflammatory and autoimmune disease portfolio with $212.5m Landos acquisition

    The deal will advance the clinical development of NX-13 for patients living with ulcerative colitis and Crohn’s disease

    - PMLiVE

    UCB presents positive long-term results for bimekizumab in hidradenitis suppurativa

    The drug was associated with sustained improvements in the signs and symptoms of the inflammatory skin disease

    2025 T40 open for submissions
    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links